The two primary FDA approved indications for the use of EPO stimulating agents are anemia secondary to chronic kidney disease and chemotherapy-induced anemia in patients with cancer, and generally limited to those with hemoglobin less than 10 g/dL due to the risk of adverse effects [9]. Here, EPO is linked to anemia.